Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

There is growing evidence that patients with Type 2 diabetes have an increased risk of
developing Parkinson's disease and share similar dysregulated pathways suggesting …

Highlights•GLP-1 analogs can cross the blood–brain barrier and stimulate the GLP-1
receptor in the brain.•Stimulation of the GLP-1 receptor has shown effects on mitochondrial …

Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, has emerged
as a promising neuroprotective agent in murine models of epilepsy and obesity-induced …

Over the last decade the important concept has emerged that microglia, similar to other
tissue macrophages, assume different phenotypes and serve several effector functions …

Parkinson's disease (PD) usually occurs due to the degeneration of dopaminergic neurons
in the substantia nigra (SN). Management of PD is restricted to symptomatic improvement …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …

Previous meta-analysis has identified the associations between diabetes mellitus (DM) and
the risk of Parkinson disease (PD). However, the results are still debatable. The purpose of …

Highly reproducible epidemiological evidence shows that type 2 diabetes (T2D) increases
the risk and rate of progression of Parkinson's disease (PD), and crucially, the repurposing …

Vildagliptin (Vilda), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been highlighted as a
promising therapeutic agent for neurodegenerative diseases as Alzheimer's and Parkinson's …